Cyclooxygenase-2(COX-2) overexpression promotes
inflammation and
tumorigenesis. COX-2 expression in response to diverse stimuli is tightly controlled to avoid persistent overexpression.
5-methoxyindole metabolites of
L-tryptophan represent a new class of compounds that control COX-2 expression at the transcriptional level. Two of the metabolites, the newly discovered
5-methoxytryptophan (5-MTP, also known as cytoguardin) and N-acetyl
5-methoxytryptamine (
melatonin) are the focus of this review. 5-MTP is produced by mesenchymal cells such as fibroblasts via
5-hydroxytryptophan (5-HTP). It inhibits COX-2 transcriptional activation induced by diverse proinflammatory and mitogenic factors.
Cancer cells are deficient in cytoguardin production which contributes to COX-2 overexpression. Fibroblast-generated 5-MTP is capable of restoring the control of COX-2 overexpression in
cancer cells. 5-MTP blocks
cancer cell migration and invasion in vitro and inhibits
tumor growth and
cancer metastasis in a xenograft model.
Melatonin possesses similar COX-2 suppressing and anti-
cancer properties albeit at supra-pharmacological concentrations. By contrast,
5-hydroxyindole metabolites of
L-tryptophan such as
5-hydroxytryptamine (
serotonin), 5-hydroxytryptophol and other
serotonin catabolites do not control COX-2 expression.
5-hydroxytryptophan inhibits COX-2 expression through conversion to 5-MTP. The physiological relevance of 5-MTP as an endogenous regulator of
inflammation and
cancer metastasis remains to be investigated. On the other hand,
5-methoxyindole metabolites of
tryptophan are valuable lead compounds for development of new anti-inflammatory drugs and
cancer chemoprevention.